Tag Archives: M&A

Merck KGaA Acquires Sigma-Aldrich for $17 Billion

Merck KGaA has announced that it has agreed to buy Sigma-Aldrich for $140 per share in cash, or a total of $17 billion. The purchase will expand the reach of Merck’s EMD Millipore chemical and equipment division, “increasing the company’s presence in North America and adding exposure to fast-growing Asian markets,” according to a press release from […]
Posted in Deals | Also tagged , , | Leave a comment

M&As: Past, Present, and Future

Pharmaceutical Technology’s Faiz Kermani looks at the long history of pharma mergers and finds no sign of the trend slowing down. It was suggested that in one week of April the total value of various rumored deals was of the order of US$100 billion, illustrating how cash-rich major pharmaceutical companies are. Many of the larger […]
Posted in Deals, Emerging Markets, Europe, Global, Guest Blog, R&D, Strategy | Also tagged , | Leave a comment

Pharma & Biotech Most Active Sector in UK M&As

The pharma, medical and biotech (PMB) sector, driven by the Novartis’s £8.6bn acquisition of GlaxoSmithKline’s oncology division, was the most active industry in UK M&A in H1 2014, with a 26.9% market share (£10.1bn), according to Mergermarket’s latest deal round-up. However M&A activity targeting the United Kingdom — standing at £37.5bn in H1 2014 — represented […]
Posted in Deals, Europe | Also tagged , , , | Leave a comment

Big Biotech Gains Offset Big Pharma Losses

Big Pharma employment dropped by 3 percent in the decade 2003–2013, allaying fears that industry consolidation and restructuring would lead to significantly reduced headcounts and payrolls, a report by EP Vantage reveals. The report shows that when it comes to pharmaceutical industry jobs, Big Biotech and specialty drugmakers are growing in significance, more than offsetting the […]
Posted in Biotech, Deals, Global, Strategy | Also tagged , , , , | Leave a comment

Pfizer–AstraZeneca: Implications for the Future of International Pharma

By Peter O’ Donnell. The Pfizer-AstraZeneca courtship raises many fascinating questions about the future shape of the international pharmaceutical industry, but it is also revealing some remarkable displays of parochialism. Even the olympian Financial Times has been displaying some nationalistic sympathies that sit oddly with its customary laissez-faire liberalism. A recent editorial seemed to argue strongly for some form […]
Posted in Deals, Europe, Global, Guest Blog, Op-Ed, Safety | Also tagged , | 2 Comments
  • Categories

  • Meta